(Q37661482)

21 August 2017

1 reference

title

Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents (English)

1 reference

attention deficit hyperactivity disorder

21 August 2017

main subject

0 references

1 reference

1 reference

1 reference

1

Karly P Garnock-Jones

1 reference

21 August 2017

2

Gillian M Keating

1 reference

21 August 2017

publication date

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

24

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

85-88

1 reference

Binding of antidepressants to human brain receptors: focus on newer generation compounds

21 August 2017

cites work

1 reference

12 December 2020

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

1 reference

12 December 2020

A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain

1 reference

12 December 2020

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Atomoxetine: a novel treatment for child and adult ADHD

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

1 reference

12 December 2020

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

1 reference

12 December 2020

Clinical pharmacology of tomoxetine, a potential antidepressant.

1 reference

12 December 2020

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder

1 reference

12 December 2020

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

1 reference

12 December 2020

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

1 reference

12 December 2020

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

1 reference

12 December 2020

Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain

1 reference

12 December 2020

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

1 reference

12 December 2020

Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.

1 reference

12 December 2020

Cardiovascular effects of atomoxetine in children, adolescents, and adults

1 reference

12 December 2020

Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.

1 reference

12 December 2020

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year

1 reference

12 December 2020

Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder

1 reference

12 December 2020

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

12 December 2020

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

1 reference

12 December 2020

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

1 reference

12 December 2020

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

1 reference

12 December 2020

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes

1 reference

12 December 2020

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

1 reference

12 December 2020

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

1 reference

12 December 2020

Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents

1 reference

12 December 2020

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

1 reference

12 December 2020

Do children and adolescents with ADHD respond differently to atomoxetine?

1 reference

12 December 2020

Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

1 reference

12 December 2020

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom

1 reference

12 December 2020

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders

1 reference

12 December 2020

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

1 reference

12 December 2020

Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder

1 reference

12 December 2020

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

1 reference

12 December 2020

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

1 reference

12 December 2020

Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites

1 reference

12 December 2020

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

1 reference

12 December 2020

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

1 reference

12 December 2020

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

12 December 2020

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

1 reference

12 December 2020

10.2165/11203670-000000000-00000

Identifiers

DOI

1 reference

21 August 2017

1 reference